Biodexa Pharmaceuticals BDRX
NASDAQ BDRX
$0.39 +0.00 (+1.17%)
As of: Oct 21, 2026 · 11:20 AM EDT

Biodexa Pharmaceuticals (BDRX) Current Deferred Revenue (2013 - 2015)

Updated

Biodexa Pharmaceuticals (BDRX) posted Current Deferred Revenue of $7.93 million for the quarter ended Dec 31, 2016, up 574.0% from $1.18 million a year earlier.

Analysis

Biodexa Pharmaceuticals (BDRX) Current Deferred Revenue (2013 - 2015) Analysis & Trends

As of Dec 31, 2016, Biodexa Pharmaceuticals' Current Deferred Revenue came in at $8.65 million, up 629.9% from the prior year.

  • Annual Current Deferred Revenue shows a three-year compound annual growth rate of 235.0% (years ended Dec 2013 to Dec 2016).
  • In prior years, Biodexa Pharmaceuticals' Current Deferred Revenue was $1.19 million in the year ended Dec 31, 2015, $41,200 in the year ended Dec 31, 2014 (-82.1%) and $230,030 in the year ended Dec 31, 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,131.67 Bn 1,100.26 Bn 19.71 Bn
2 Johnson & Johnson 614.28 Bn 532.81 Bn 17.26 Bn
3 AbbVie 503.23 Bn 476.34 Bn 12.70 Bn
4 Merck 368.28 Bn 322.66 Bn 12.21 Bn
5 Novartis Ag 298.22 Bn 262.21 Bn 11.24 Bn
6 Astrazeneca 261.55 Bn 235.23 Bn 12.86 Bn
7 Amgen 235.92 Bn 191.31 Bn 7.24 Bn
8 Gilead Sciences 190.78 Bn 164.98 Bn 6.22 Bn
9 Pfizer 169.66 Bn 116.31 Bn 10.94 Bn
10 Biodexa Pharmaceuticals 4,025.62 -23.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 2.04 Mn
Dec 31, 2014 244,434.05
Dec 31, 2013 242,478.24
API Access

Biodexa Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BDRX&period=max&api_key=YOUR_API_KEY